

This is a repository copy of *An evaluation of the influence of the publication of the UK National Institute for Health and Care Excellence's guidance on Hypertension in Pregnancy: a retrospective analysis of clinical practice.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/156364/>

Version: Accepted Version

Article:

Farrar, Diane, Tuffnell, Derek and Sheldon, Trevor Andrew orcid.org/0000-0002-7479-5913 (Accepted: 2020) An evaluation of the influence of the publication of the UK National Institute for Health and Care Excellence's guidance on Hypertension in Pregnancy: a retrospective analysis of clinical practice. BMC Pregnancy and Childbirth. ISSN 1471-2393 (In Press)

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Supplementary table 1 Prevention of pre-eclampsia and management of pre-existing hypertension by hospital (A-E). Values are n (%) of the included/eligible hospital population

	NICE hypertension in pregnancy recommendations	
	Before guidance	After guidance
High risk of pre-eclampsia		
A	6 (4)	5 (3)
B	33 (9)	15 (4)
C	14 (9)	37 (23)
D	11 (3)	19 (5)
E	9 (4)	17 (9)
Moderate risk of pre-eclampsia		
A	9 (6)	6 (4)
B	42 (12)	27 (8)
C	10 (7)	12 (10)
D	39 (11)	64 (18)
E	5 (3)	7 (4)
Aspirin prescription for high risk women		
A	1 (17)	3 (60)
B	2 (6)	8 (53)
C	3 (21)	16 (43)
D	3 (27)	17 (89)
E	1 (11)	6 (35)
Aspirin prescription for moderate risk women		
A	-	-
B	-	9 (33)
C	-	4 (33)
D	2 (5)	49 (77)
E	1 (20)	1 (14)
Diagnosis of pre-existing hypertension		
A	-	-
B	3 (1)	1 (<1)
C	6 (4)	10 (6)
D	8 (2)	25 (7)
E	-	5 (3)
ACE or ARBs used prior to or in early pregnancy		
B	-	-
C	-	-
D	2 (33)	4 (40)
E	-	6 (25)
B	-	-
Alternatives to ACE or ARBs prescribed		
A	-	-
B	-	-
C	2 (100)	4 (100)
D	-	4 (67)
E	-	-

ACE = Angiotensin-converting enzyme

ARB = Angiotensin receptor blockers

Supplementary table 2 Antenatal surveillance by hospital (A-E). Values are n (%) of the included/eligible hospital population

	NICE hypertension in pregnancy recommendations	
	Before guidance	After guidance
Blood Pressure recorded at every antenatal visit		
A	92 (61)	110 (74)
B	340 (90)	299 (87)
C	89 (55)	105 (65)
D	260 (70)	269 (72)
E	181 (87)	130 (68)
If not recorded at every visit how often omitted		
once		
A	42 (72)	26 (67)
B	29 (76)	25 (56)
C	53 (73)	37 (66)
D	72 (64)	68 (64)
E	21 (77)	43 (72)
twice		
A	13 (22)	9 (23)
B	6 (16)	10 (22)
C	11 (15)	14 (25)
D	26 (23)	19 (18)
E	5 (19)	12 (20)
three		
A	2 (3)	4 (10)
B	2 (5)	8 (18)
C	7 (10)	3 (5)
D	5 (4)	12 (11)
E	-	3 (5)
four		
A	1 (2)	0 (-)
B	1 (3)	2 (4)
C	1 (1)	1 (1)
D	6 (5)	3 (3)
E	-	1 (2)
≥Five times		
A	-	-
B	-	-
C	1 (1)	-
D	3 (3)	4 (4)
E	1 (4)	-
Proteinuria recorded at every antenatal visit		
A	17 (11)	30 (20)
B	122 (32)	89 (26)
C	36 (22)	31 (19)
D	218 (59)	198 (53)
E	48 (23)	69 (36)
If not recorded at every antenatal visit how often omitted		
once		
A	38 (29)	49 (42)
B	77 (30)	37 (16)
C	68 (54)	63 (48)
D	96 (62)	116 (66)
E	62 (39)	50 (42)
twice		

**NICE hypertension in pregnancy
recommendations**

	Before guidance	After guidance
A	31 (23)	31 (26)
B	96 (38)	68 (27)
C	35 (28)	35 (27)
D	38 (25)	28 (16)
E	46 (29)	33 (28)
three		
A	26 (20)	22 (19)
B	47 (18)	77 (30)
C	17 (13)	18 (14)
D	10 (6)	17 (10)
E	26 (16)	13 (11)
four		
A	17 (13)	8 (7)
B	21 (8)	39 (15)
C	6 (5)	9 (7)
D	6 (4)	5 (3)
E	14 (9)	12 (10)
≥Five times		
A	21 (16)	8 (7)
B	15 (6)	34 (13)
C	1 (<1)	5 (4)
D	4 (3)	11 (6)
E	12 (8)	12 (10)

Supplementary table 3 Diagnosis and treatment. Values are n (%) of the included/eligible hospital population

	NICE hypertension in pregnancy recommendations	
	Before guidance	After guidance
Gestational hypertension or pre-eclampsia^a		
A	14 (9)	9 (6)
B	92 (24)	55 (34)
C	18 (11)	24 (6)
D	91 (24)	97 (26)
E	12 (6)	10 (5)
Blood pressure equal or exceeding recommended treatment threshold^b		
A	3 (21)	2 (22)
B	9 (10)	13 (24)
C	7 (40)	5 (21)
D	33 (36)	37 (38)
E	2 (17)	5 (50)
Antihypertensive prescription (for gestational hypertension and Pre-eclampsia):		
No antihypertensive		
A	9 (64)	2 (22)
B	81 (89)	11 (20)
C	6 (33)	18 (75)
D	37 (41)	21 (22)
E	6 (50)	1 (10)
Labetalol		
A	5 (36)	7 (78)
B	9 (10)	40 (73)
C	10(50)	6 (25)
D	29 (32)	59 (60)
E	5 (42)	8 (80)
Other antihypertensive prescribed ^c		
A	-	-
B	1 (1)	4 (7)
C	2 (11)	-
D	24 (27)	17 (18)
E	1 (8)	1 (10)
Missing		
A	-	-
B	1 (1)	-
C	-	-
D	1 (1)	-
E	-	-
Protein estimated when hypertension identified		
A	13 (93)	8 (89)
B	59 (65)	52 (35)
C	12 (67)	21 (88)
D	61 (67)	58 (60)
E	10 (83)	9 (90)
Method used to estimate protein:		
24 hour urine		
A	-	-
B	1 (2)	-
C	8 (67)	-
D	3 (5)	6 (10)

	NICE hypertension in pregnancy recommendations	
	Before guidance	After guidance
E	1 (10)	-
Automated reagent strip reading		
A	-	4 (50)
B	-	12 (23)
C	-	-
D	6 (10)	1 (2)
E	-	-
Spot PCR		
A	2 (15)	3 (38)
B	7 (12)	34 (65)
C	-	11 (52)
D	37 (61)	45 (46)
E	1 (10)	5 (56)
Reagent strip visual inspection		
A	11 (85)	1 (13)
B	32 (54)	6 (12)
C	4 (33)	10 (48)
D	12 (20)	5 (9)
E	8 (80)	4 (44)
Other estimation		
A	-	-
B	19 (32)	-
C	-	-
D	-	1 (2)
E	-	-
Unclear		
A	-	-
B	-	-
C	-	-
D	3 (5)	-
E	-	-
Missing		
A	1 (8)	-
B	-	-
C	-	-
D	-	-
E	-	-
Admitted due to HDP		
A	5 (36)	6 (67)
B	14 (15)	12 (50)
C	16 (89)	42 (76)
D	50 (56)	65 (67)
E	7 (58)	2 (20)
Care on hospital admission:		
Highest mean systolic BP prior to admission (for HDP)		
A	157	150
B	150	153
C	150	151
D	150	159
E	146	160
Highest mean diastolic BP prior to admission (for HDP)		
A	103	98
B	98	109
C	98	133
D	97	101

NICE hypertension in pregnancy recommendations		
	Before guidance	After guidance
E	97	112
Protein estimated prior to admission		
A	5 (100)	6 (100)
B	13 (93)	11 (92)
C	7 (44)	31 (82)
D	40 (80)	42 (65)
E	2 (73)	2 (100)
Anti-hypertensive prescribed ^c		
A	5 (100)	4 (67)
B	6 (43)	4 (33)
C	8 (50)	27 (64)
D	24 (50)	42 (65)
E	3 (43)	2 (100)
Existing hypertensive medication increased		
A	-	1 (17)
B	1 (7)	2 (17)
C	3 (19)	8 (19)
D	4 (8)	8 (12)
E	-	-
No medication prescribed or increased		
A	-	1 (17)
B	7 (50)	6 (50)
C	5 (31)	7 (17)
D	20 (42)	15 (23)
E	4 (57)	-
Labetalol prescribed		
A	5 (100)	4 (80)
B	6 (86)	2 (33)
C	6 (55)	25 (71)
D	16 (57)	32 (64)
E	2 (67)	1 (50)
Labetalol increased		
A	-	1 (20)
B	1 (14)	4 (67)
C	1 (9)	8 (23)
D	3 (11)	7 (14)
E	-	1 (50)
Other antihypertensive prescribed ^d		
A	-	-
B	-	-
C	4 (36)	2 (6)
D	9 (32)	11 (22)
E	1 (33)	-
For all women with a HDP diagnosis:		
Was early Birth <37 weeks gestation offered due to HDP~		
A	2 (14)	1 (13)
B	-	4 (17)
C	9 (50)	14 (25)
D	8 (9)	15 (15)
E	1 (8)	1 (10)
If early Birth <37 weeks gestation offered due to HDP:		
Was BP \geq 160/110		
A	1 (50)	-
B	-	-
C	-	1 (7)

	NICE hypertension in pregnancy recommendations	
	Before guidance	After guidance
D	-	3 (20)
E	1 (5)	1 (100)
No evidence of BP \geq 160/110		
A	1 (50)	1 (100)
B	4 (44)	2 (50)
C	4 (50)	3 (21)
D	-	2 (13)
E	9 (45)	-
'Other' concerns		
A	-	-
B	-	2 (50)
C	5 (56)	10 (71)
D	4 (50)	10 (67)
E	1 (100)	-
Was early Birth \geq 37 weeks gestation offered due to HDP		
A	4 (33)	6 (86)
B	19 (21)	9 (45)
C	4 (44)	33 (80)
D	34 (41)	51 (62)
E	7 (64)	4 (44)
If early Birth \geq37 weeks gestation offered due to HDP:		
Was BP \geq 160/110		
A	-	-
B	1 (5)	-
C	1 (25)	-
D	6 (18)	5 (10)
E	-	-
No evidence of BP \geq 160/110		
A	3 (75)	3 (50)
B	18 (95)	9 (100)
C	3 (75)	17 (52)
D	23 (68)	30 (59)
E	7 (100)	1 (25)
'Other' concerns		
A	1 (5)	3 (50)
B	-	-
C	-	16 (48)
D	5 (15)	16 (31)
E	-	3 (75)

^adiagnosis of gestational hypertension or pre-eclampsia or BP equal to or greater than 140/90 on two occasions at least 4 hours apart, this includes two readings at least 4 hours apart with a systolic BP equal to or greater than 140 with a normal diastolic or a diastolic equal to or greater than 90 with a normal systolic

^bBP greater than or equal to recommended treatment threshold 150/100 on two occasions at least 4 hours apart

^cone or more drugs prescribed or increased

^dmethyl dopa, nifedipine

Supplementary table 4 Postnatal management of women diagnosed with a HDP. Values are n (%) of the included/eligible hospital population

	NICE hypertension in pregnancy guidance	
	Before guidance	After guidance
Informed of increased risk of HDP in future pregnancy		
A	-	-
B	1 (1)	-
C	2 (11)	9 (16)
D	1 (1)	9 (9)
E	-	2 (20)
Medical review conducted at the postnatal review		
A	-	-
B	-	-
C	8 (44)	4 (7)
D	3 (3)	4 (4)
E	2 (16)	1 (10)
Unknown- advised to see GP for postnatal review		
A	9 (64)	9 (100)
B	24 (26)	19 (79)
C	9 (50)	50 (91)
D	82 (91)	89 (92)
E	8 (67)	9 (90)
No evidence		
A	5 (36)	-
B	68 (74)	5 (21)
C	1 (6)	1 (2)
D	5 (6)	4 (4)
E	2 (17)	-

HDP=hypertensive disorder of pregnancy